Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. 27 November 2019. Dan Rose.

Executive Summary

LimFlow expects the US Food and Drug Administration to approve its percutaneous deep vein arterialization system for patients with advanced critical limb ischemia by the end of 2021. See what Lim Flow's CEO, Dan Rose, said about it here.

“The patients are, essentially, on the cusp of major limb amputation and we are keeping them with their legs and their wounds are fully healed which, in many ways, dramatically reduces the risk of a future amputation.” – Dan Rose, CEO, LimFlow

  • Find out more: LimFlow On Target For 2021 US Launch Of Deep Vein Arterialization System

     

Click here for a free trial of Medtech Insight

Related Content

Topics

UsernamePublicRestriction

Register

MT125948

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel